Peers

Piramal Pharma Ltd. operates in a competitive pharmaceuticals market characterized by significant variations in growth, profitability, and valuation among peers. While Piramal shows moderate growth and profitability metrics, some competitors demonstrate superior performance, making them potential leaders in the sector. However, Piramal's metrics suggest it is positioned well relative to the market, offering a balance between growth and valuation.

• • Piramal Pharma shows strong revenue growth but lower profitability compared to top competitors.
• • Financially, Piramal has moderate debt levels but could improve its return metrics.
• • Compared to peers, Piramal is reasonably valued, making it an attractive option for growth-focused investors.

• • Cipla Ltd.: Highest ROE and strong revenue growth, indicating both profitability and efficiency.
• • Dr. Reddy's Laboratories Ltd.: Strong profitability metrics with low valuation ratios, making it a compelling pick.
• • Mankind Pharma Ltd.: Exceptional revenue growth and good profitability, marking it as a standout performer.